Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci by Clark AD et al.
Lymphocyte DNA methylation mediates genetic
risk at shared immune-mediated disease lociAlexander D. Clark, BSc,a Nisha Nair, PhD,b,c Amy E. Anderson, PhD,a Nishanthi Thalayasingam, BM, Bch, MA,a
Najib Naamane, MSc,a Andrew J. Skelton, MSc,d Julie Diboll, BSc,a Anne Barton, MBChB, PhD,b,c Stephen Eyre, PhD,b,c
John D. Isaacs, MBBS, PhD,a,e Arthur G. Pratt, MBChB, PhD,a,e* and Louise N. Reynard, PhDf* Newcastle upon Tyne and
Manchester, United KingdomGRAPHICAL ABSTRACTBackground: Defining regulatory mechanisms through which
noncoding risk variants influence the cell-mediated
pathogenesis of immune-mediated disease (IMD) has emerged
as a priority in the post–genome-wide association study era.
Objectives: With a focus on rheumatoid arthritis, we sought
new insight into genetic mechanisms of adaptive immuneFrom aNewcastle University Translational and Clinical Research Institute, Newcastle
upon Tyne; bVersus Arthritis Centre for Genetics and Genomics, Centre for Musculo-
skeletal Research, Institute of Inflammation and Repair, University of Manchester;
cNIHR Manchester Musculoskeletal BRC, Manchester University NHS Foundation
Trust, Manchester; dthe Bioinformatics Support Unit, Faculty of Medical Sciences,
Newcastle University, Newcastle upon Tyne; ethe Musculoskeletal Services Direc-
torate, Newcastle upon Tyne Hospitals NHS Trust; and fNewcastle University Biosci-
ences Institute, Newcastle upon Tyne.
*These authors contributed equally to this work.
Andrew J. Skelton, MSc, is currently at UCB, Slough, United Kingdom.
Disclosure of potential conflict of interest: Funding for this work came from theAcademy
of Medical Sciences, the JGW Patterson Foundation, and an unrestricted research
grant from Pfizer. It was further supported by the National Institute of Health Research
(NIHR) Newcastle Biomedical Research Centre at Newcastle Hospitals Foundation
Trust and Newcastle University, the NIHR Manchester Musculoskeletal Biomedical
Research Centre, and the British Medical Association (Doris Hillier Award to A.G.P.).
Newcastle researchers received infrastructural support via the Versus Arthritis
Research into Inflammatory Arthritis Centre. N.T. was supported by a Wellcome
Trust clinical training fellowship. N. Nair was funded by an MRC/Versus Arthritisdysregulation to help prioritize molecular pathways for
targeting in this and related immune pathologies.
Methods: Whole-genome methylation and transcriptional data
from isolated CD41 T cells and B cells of more than 100
genotyped and phenotyped patients with inflammatory
arthritis, all of whom were naive to immunomodulatorystratified medicine award (grant no. MR/K015346/1), and data generation was
supported by Versus Arthritis (grant no. 21754).
Availability of data and materials: The DNA methylation data from CD41 and B cells
used in this study, together with paired transcriptome data, are available in the Gene
Expression Omnibus database (accession no. GSE137634; http://www.ncbi.nlm.nih.
gov/geo). Annotated scripts may be found at https://github.com/aclark5/
Lymphocyte_meQTL. Any additional original data analyzed during the current study
are accessible via the corresponding author on reasonable request.
Received for publication April 10, 2019; revised December 4, 2019; accepted for publi-
cation December 10, 2019.
Corresponding author: Arthur G. Pratt, MBChB, PhD, Translational and Clinical
Research Institute (Musculoskeletal Research Group), Newcastle University, Newcas-
tle upon Tyne NE2 4HH, UK. E-mail: arthur.pratt@ncl.ac.uk.
0091-6749
 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY li-
cense (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.jaci.2019.12.910
1
Abbreviations used
CIT: Causal inference test
DNAm: DNA methylation
eQTL: Expression quantitative trait locus
eQTM: Expression quantitative trait methylation
FDR: False-discovery rate
GWAS: Genome-wide association study
IMD: Immune-mediated disease
LD: Linkage disequilibrium
meQTL: Methylation quantitative trait locus
MS: Multiple sclerosis
OA: Osteoarthritis
RA: Rheumatoid arthritis
SNP: Single nucleotide polymorphism
TFBS: Transcription factor binding site
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2 CLARK ET ALtreatments, were obtained. Analysis integrated these
comprehensive data with genome-wide association study
findings across IMDs and other publicly available resources.
Results: We provide strong evidence that disease-associated
DNAvariants regulate cis-CpG methylation in CD41 Tand/or B
cells at 37% RA loci. Using paired, cell-specific transcriptomic
data and causal inference testing, we identify examples where
site-specific DNA methylation in turn mediates gene expression,
including FCRL3 in both cell types and ORMDL3/GSDMB,
IL6ST/ANKRD55, and JAZF1 in CD41 T cells. A number of
genes regulated in this way highlight mechanisms common to
RA and other IMDs including multiple sclerosis and asthma, in
turn distinguishing them from osteoarthritis, a primarily
degenerative disease. Finally, we corroborate the observed
effects experimentally.
Conclusions: Our observations highlight important mechanisms
of genetic risk in RA and the wider context of immune
dysregulation. They confirm the utility of DNA methylation
profiling as a tool for causal gene prioritization and, potentially,
therapeutic targeting in complex IMD. (J Allergy Clin Immunol
2020;nnn:nnn-nnn.)
Key words: Rheumatoid arthritis, adaptive immunity, immune-
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Genome-wide association studies (GWASs) have shed light on
the genetic architecture of common immune-mediated diseases
(IMDs). However, disease-associated variants are typically
noncoding, leaving the mechanism(s) through which they
contribute to etiology unclear. For example, to date single
nucleotide polymorphisms (SNPs) at more than 100 genomic
loci have been found to influence rheumatoid arthritis (RA)
susceptibility,1 and their enrichment at enhancer elements that are
active in CD41 T and B cells suggests that substantial risk is
conferred via transcriptional dysregulation of the adaptive
immune system.2-4 By mapping allelic effects on gene
expression—termed expression quantitative trait loci
(eQTLs)—we and others have sought to prioritize candidate
causal genes in these cells.5-8 However, SNPs also modulate
DNA methylation (DNAm; methylation quantitative trait loci
[meQTLs]),9-15 whose role in transcriptional regulation is now
well established.16 The colocalization of meQTLs with eQTLs
therefore implicates DNAm as a potential mediator of observed
eQTL effects in some cases,9-15 and intriguing associations
between site-specific DNAm and the development of RA have
been documented in several cell types.17-23 Identifying instances
in which RA-associated SNPs impact DNAm in a manner that
affects lymphocyte gene transcription could substantially refine
the regulatory landscape of candidate genes in IMDs such as RA.
eQTL effects often differ between cell types10,12,24 and
although deconvolution methods can be applied to mixed-cell
populations,25 the role of meQTLs in disease pathogenesis should
ideally be validated in isolated subsets. Furthermore, DNAm and
gene expression may be shaped by the local microenvironment in
which a cell exists,21 with certain eQTL effects becoming
evident only on cell stimulation or in the context of active
inflammation,26,27 and site-specific DNAm may be similarly
linked to acute-phase response.28,29 Hence, meQTL-mediated
mechanisms of genetic risk are optimally evaluated at a cellularlevel in relevant patient cohorts, and doing so should yield
important insight into complex disease pathogenesis. Here, we
used genome-wide molecular profiling to comprehensively inves-
tigate the relationship between RA-associated genetic variants,
DNAm, and gene expression in primary CD41 T and B cells of
drug-naive patients with early arthritis. Our findings are
interpreted in the context of publicly available data sets.METHODS
Fully detailedmethods are described in this article’sMethods section in the
Online Repository at www.jacionline.org.Lymphocyte-specific nucleic acid isolation from
patients
Patients of Northern European ancestry with suspected inflammatory
arthritis were recruited before treatment with immunomodulatory drugs as
described.30 Patients with RA were classified using current, internationally
accepted criteria,31 and matched with disease controls in respect of
demographic and clinical characteristics. CD41 T cells and CD191 B cells
were isolated from fresh peripheral blood using magnetic bead–based
positive selection, with purity confirmed by flow cytometry, and DNA/RNA
extracted as described.8 The study was approved by the Newcastle and North
Tyneside Regional Ethics Committee, and all participants gave informed
consent.Genotyping
Genotyping was carried out using an Illumina Human CoreExome-24
version 1-0 array (Illumina, San Diego, Calif). Samples and SNPs with a call
rate of less than 98% were excluded, as were SNPs with a minor allele
frequency of less than 0.01 or Illumina GenomeStudio cluster separation of
less than 0.4. Data were prephased with SHAPEIT232 and imputed to the 1000
Genomes Phase 3 reference panel using IMPUTE2,33 with imputed SNPs
having INFO scores of less than 0.8 being removed. Quantitative trait locus
analysis was limited to SNPs for which there were 3 or more individuals per
genotype or, in the absence of minor allele homozygotes, 8 or more
heterozygous individuals.DNAm quantification and meQTL analysis
Four hundred nanogram of DNA was bisulphite-converted and DNAm
quantified using the Infinium MethylationEPIC BeadChip (Illumina). After
independent preprocessing and functional normalization34 of CD41 T- and
B-cell data, probe filtering was performed and surrogate variable analysis
used to estimate confounding variables (surrogate variable analysis
package35), conserving the effects of disease diagnosis. These were then
TABLE I. Description of patient cohorts included in the meQTL
analysis of CD41 T cells and B cells
Characteristic
Patients
with RA
Disease
controls
P
value*
CD41 T cells
No. of patients 43 60
Age (y) 58 (50-69) 54 (46-63) .13
Sex: female, % 67 70 .78
C-reactive protein (mg/L) 9 (5-13) 7.5 (5-13.5) .24
Erythrocyte sedimentation rate
(mm/h)
19 (7-32) 15 (9-29) .74
CCP-positive, % 47 —
RF-positive, % 58 —
Tender 28 3 (0-11) 2 (0-5.5) .39
Swollen 28 1 (0-3) 0 (0-2) .51
Diagnosis in disease controls, %
OA 8
Other noninflammatory arthritis 7
Spondyloarthropathy
(PsA, ReA, EA)
45
Crystal arthropathy 15
Other inflammatory arthritis 13
Other/undifferentiated 12
B cells
No. of patients 46 73
Age (y) 57 (50-68) 55 (46-64.5) .34
Sex: female, % 74 71 .75
C-reactive protein (mg/L) 9 (5-13) 7 (5-14.5) .14
Erythrocyte sedimentation rate
(mm/h)
19.5 (5.75-34.5) 16 (9-30.75) .99
CCP-positive, % 54 —
RF-positive, % 61 —
Tender 28 3 (1-9) 3 (1-6) .50
Swollen 28 1 (0-3) 0 (0-3) .52
Diagnosis in disease controls
OA 8
Other noninflammatory arthritis 7
Spondyloarthropathy
(PsA, ReA, EA)
48
Crystal arthropathy 11
Other inflammatory arthritis 8
Other/undifferentiated 18
Statistics presented are median (interquartile range) for continuous data and
percentages for discrete data.
*P values reported are calculated between RA and disease control groups using a x2
test for categorical data, or Mann-Whitney test for continuous data.
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package.36 False-discovery rate (FDR) was calculated across all tests, and
independent signals distinguished by SNP clumping. In addition, an
interaction analysis (Genotype 3 Diagnosis) was performed to identify
putative disease-specific effects. RA-meQTLs were defined where disease
risk loci, extracted from publicly available GWAS catalog studies,37 mapped
to the meQTL regulatory SNP, with Bayesian colocalization applied to
provide additional evidence for a shared causal variant.38 GWAS variants
from studies of multiple sclerosis (MS), asthma, and osteoarthritis (OA)
were similarly leveraged to extend analyses beyond RA loci.
Gene expression quantification
CD41T- andB-cell transcriptomic datawere generated using theHumanHT-
12 v4 Expression BeadChip (Illumina) as has been described.8 Failed probes
were removed before background correction and quantile normalization in
Limma.39 Additional probes were filtered where they mapped to (1) sex
chromosomes, (2) repeat or intronic/intergenic regions, or (3) unmapped
regions. Surrogate variable analysis was performed as for DNAm data.35
Chromatin state and transcription factor binding
enrichment analysis
Cis-CpG sites associated with GWAS loci were mapped to chromatin state
information from primary TH cells and primary B cells as defined by the
RoadmapEpigenomics consortium,40 and similarly with chromatin immunopre-
cipitation sequencing–derived transcription factor binding site (TFBS) data from
the Encyclopaedia of DNA Elements project.41,42 Enrichment of risk-associated
meQTL CpGs at specific chromatin states and TFBSs was determined with the
Fisher exact test, with nonrisk cis-CpGs used as background for enrichment
analyses. Gene ontology enrichment analysis of biological pathways was
performed using the gometh function within the missMethyl package.43
Expression quantitative trait methylations and
causal inference
At risk-associated cis-CpG sites, Spearman rho (FDR < 0.01) was applied
with transcripts within 6500 Kb to identify expression quantitative trait
methylations (eQTMs). To infer directionality of SNP-CpG-transcript
associations, a causal inference test (CIT) was applied,44 inputting triplets at
disease risk loci that demonstrated both cis-meQTL and cis-eQTM effects.
FDR values were determined by performing 1000 data permutations.
Validation of quantitative trait locus effects by
pyrosequencing and luciferase reporter assay
Cis-meQTL effects at 3 loci implicated by CIT were replicated by
pyrosequencing45 in an independent cohort of genotyped patients with early
arthritis. Analysis of allelic expression imbalance was used to further confirm
the eQTL effect at the exemplar FCRL3 locus in CD41 T cells.46 Finally, the
inferred DNAm-mediated regulation downstream of the regulatory SNP was
assessed experimentally at this locus using a luciferase reporter assay in the
Jurkat T-cell line. Formethodological detail, see this article’sMethods section
in theOnline Repository (primer sequences for all pyrosequencing andFCRL3
promoter amplification are listed in Table E1 in this article’s Online
Repository at www.jacionline.org).
Statistical analysis
Statistical analyses were performed in R (http://www.R-project.org/)
version 3.4.4 and GraphPad Prism 7 (San Diego, Calif). A P value of less
than .05 was considered significant unless otherwise stated.
RESULTS
Patient cohort and clinical characteristics
Paired genotype and DNAm data were available from 141
patients with early arthritis (CD41 T cells alone in 22 cases,
B cells alone in 38, and both cell types in 81). The demographicand clinical characteristics of donors are presented for each cell
type in Table I. Comparator groups within each cohort (RA and
non-RA) were matched for major demographic and clinical
parameters including age, sex, and markers of systemic
inflammation (C-reactive protein; erythrocyte sedimentation
rate). The disease control group comprised a range of diagnoses,
most being spondyloarthropathies.
Genome-wide mapping highlights both common
and differential cis-meQTL effects between
CD41 T and B cells in early arthritis
meQTL effects (cis and trans) were mapped genome-wide in
each lymphocyte subset across all patients (Fig 1, A; Fig E1 in
this article’s Online Repository at www.jacionline.org provides
an overview of study design and key findings). We predominantly
identified meQTLs acting in cis, defined as an SNP-CpG
FIG 1. meQTL mapping genome-wide in CD41 and B cells of patients with early arthritis. A, SNP and CpG
coordinates of all independent cis/trans-meQTL effects mapped in both CD41 T cells (left) and B cells (right)
across patients with early arthritis. Cis-meQTLs denoted by circles and transmeQTLs by squares, with the
color reflecting the –log10 FDR value of the association. B, Distance between regulatory SNP and its cognate
CpG site plotted against effect size (absolute regression coefficient, b) for all cis-meQTLs. C, Exemplar plots
of cis-meQTLs identified exclusively CD41 T cells (left), common to both cell types (middle), or exclusively in
B cells (right). Boxplots display the median, 25th and 75th percentiles. Whiskers extend to the highest/
lowest value that is no greater than 1.5 3 interquartile range from the 75th/25th percentile, respectively.
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4 CLARK ET ALassociation occurring over a distance of less than 1 megabase (see
this article’s Methods section in the Online Repository). Focusing
on these, 58,625 independent cis-meQTLs were active in CD41 T
cells and 60,315 in B cells (Fig 1, A; see Tables E2 and E3 in thisarticle’s Online Repository at www.jacionline.org), involving
53,131 and 53,925 individual CpGs, respectively.
A diminution of meQTL effect size (b coefficient) was
observed with increasing SNP-CpG distance, consistent with a
J ALLERGY CLIN IMMUNOL
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Correspondingly, 87% of the observed cis-meQTLs in
CD41 T cells and 85% in B cells occurred over a distance
of less than 250 kb. Exemplar plots of significant SNP-CpG
cis-regulatory associations that were identified in both cell types,
or showed significant associations only in CD41T cells or B cells,
are shown in Fig 1,C. A substantial proportion of CpGs subject to
cis-meQTL effects (cis-CpGs) were common to CD41 T and B
cells; indeed, a powerful empirical Bayes analytical approach47
suggested that as many as 68% of associations in either cell
type were shared (see Fig E2, A and B, in this article’s Online
Repository at www.jacionline.org). The direction and effect size
of overlapping cis-meQTLs were approximately equivalent
between CD41 T and B cells, though opposing allelic effects
appeared to be exerted at 47 CpGs (Fig E2, C, shown in red;
see Table E4 in this article’s Online Repository at
www.jacionline.org). We also explored the possibility that
meQTL effects may be impacted by disease phenotype (RA vs
non-RA; see this article’s Methods section in the Online
Repository). Such effects in cis were scarce, with only 1 example
occurring in B cells (see Fig E3 and Table E5 in this article’s
Online Repository at www.jacionline.org).cis-CpGs at-risk loci are functionally enriched
according to cell type–specific chromatin
architecture
We sought evidence that site-specific DNAm represents a
functional intermediary of genetic risk for complex disease,
identifying instances in which meQTL regulatory variants map to
risk loci from published GWAS data.37 First focusing on RA,
linkage disequilibrium (LD) blocks harboring risk-associated
SNPs from case-control studies were intersected with the meQTL
landscape of early arthritis lymphocytes. Of the independent RA
risk loci represented in our data sets (104 and 107 for CD41 Tand
B cells, respectively), 24 exhibited cis-regulatory effects
on DNAm in both cell types, with 8 identified uniquely in
CD41 T cells and 9 in B cells (Fig 2; see Table E6 in this article’s
Online Repository at www.jacionline.org). An independent,
Bayesian statistical approach provided strong corroborative
evidence (PP4 > 0.75; see this article’s Methods section in the
Online Repository) that disease- and methylation-associated
variants colocalized in most of these cases (76% of RA
cis-meQTLs in CD41 T cells, 79% in B cells; see Table E6).
CpGs identified were typically located within, or proximal to,
genes previously proposed to be candidates at RA risk loci1
and/or those observed to be the subject of lymphocyte eQTLs
described by us and others5-8 (Fig 2).
To understand better the regulatory effects of disease-
associated loci, we mapped cis-CpGs genome-wide to
cell-specific chromatin states as described by the Roadmap
Epigenomics Project.40 At RA risk loci in CD41 T cells, such
CpGs were enriched at enhancer elements and depleted at
transcribed and repressed regions, relative to those associated
with non-risk loci (Fig 3,A). Analogous enrichment was observed
at transcription start site–flanking regions in B cells, again with
underrepresentation at sites of repressed chromatin (Fig 3, A).
Because DNAm can influence protein-DNA interactions,48
meQTLs could confer disease risk via altered transcription factor
binding. Consistent with this, by mapping meQTL-associated
CpGs to TFBSs determined from publicly available data,41,42we found that those at RA risk loci of CD41 T and B cells were
overrepresented at nuclear factor kappa B subunit p65-binding
sites (see Table E7 in this article’s Online Repository at www.
jacionline.org). Gene ontology analysis revealed processes
relating to immune cell function/development to be enriched at
RA meQTL cis-CpGs of both cell types, compared with those
outside risk loci (Fig 3, B; see Table E8 in this article’s Online Re-
pository at www.jacionline.org). Prominent among these were
regulation of the B-cell receptor signaling pathway and regula-
tion of antigen receptor–mediated signaling pathway.
Twenty of 41 (49%) RA-associated cis-meQTLs identified
were noted to reside at risk loci shared with other IMDs
(Table E6). Focusing on asthma and MS, we therefore explored
whether cis-meQTLs at risk loci mapped similarly to
cell-specific chromatin states in such diseases, and contrasted
this with OA, an arthropathy in which dysregulated adaptive
immunity is considered a comparatively minor contributor to
pathogenesis. Across all traits, risk-associated CpG sites were
depleted in repressed chromatin regions relative to nonrisk
CpGs. However, we observed a particularly marked enrichment
of IMD-associated CpG sites in CD41 T-cell enhancers
(>_2-fold compared with nonrisk CpGs; see Fig 3, A and C, left
panels).Cis-CpGs associatedwith OA risk loci were less enriched
in lymphocyte regulatory elements (eg, 1.6-fold in CD41 T-cell
enhancers) but were, in contrast, overrepresented in transcribed
regions (Fig 3, C, right panel). MS-associated cis-CpGs (though
not asthma-associated equivalents) were enriched at RELA,
BATF, and RUNX3 TFBSs (see Tables E9 and E10 in this article’s
Online Repository at www.jacionline.org). Ontology enrichment
analyses of both IMD-associated meQTL landscapes implicated
lymphocyte activation/differentiation, in addition to cytokine
and type 2 immune responses at B-cell meQTLs in asthma (see
Tables E11 and E12 in this article’s Online Repository at
www.jacionline.org). Conversely, the OA-associated meQTL
landscape highlighted a distinct TFBS profile (see Table E13 in
this article’s Online Repository at www.jacionline.org), and
pathways related to cellular apoptosis and endopeptidase
activity (see Table E14 in this article’s Online Repository at
www.jacionline.org). Taken together, these data point to a role
for DNAm in modulating functionally relevant transcriptional
activity of lymphocyte subsets that are most prominent at shared
IMD risk loci.DNAm mediates eQTL effects at RA risk loci
Given the potential of DNAm to influence gene expression, we
incorporated paired, cell-type–specific transcriptome data to
identify instances in which CpG methylation was simultaneously
correlated with risk variants (meQTLs) and transcript levels of
genes in cis (eQTMs). Focusing once more on RA, eQTMswithin
a 6500-kb window of cis-CpG sites at disease risk loci were
mapped. Forty-two such instances were identified in CD41
T cells, representing 20 CpGs and 8 unique genes (ANKRD55,
JAZF1, FCRL3, ORMDL3, IL6ST, GSDMB, C11orf10, and
TAX1BP1; see Table E15 in this article’s Online Repository at
www.jacionline.org). In B cells, 65 associations encompassed
29 CpGs and 14 unique genes (FAM167A, ORMDL3, GSDMB,
IKZF3, FCRL3, XKR6, BLK, CCR6, SLC4A7, CDK12, IRF5,
MSL1, NEIL2, and TXNDC11; see Table E16 in this article’s
Online Repository at www.jacionline.org). In both cell types,
most associations were inverse, with increased methylation
FIG 2. Manhattan plots show significance of cis SNP-CpG associations satisfying the genome-wide FDR
threshold that maps to LD blocks harboring RA risk variants from the GWAS Catalog.37 CD41 T-cell
associations are shown in the upper plot, and B-cell associations are shown in the lower plot. SNP-CpG
pairs highlighted in color are the top independent associations at each locus after SNP clumping. Gene
names are given for instances where CpG sites fall at annotated genes in the Illumina annotation file.
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6 CLARK ET ALcoinciding with decreased transcript levels (79% unique
CpG-Gene pairs in CD41 T cells, 66% B cells). Notably,
DNAm at several CpG sites correlated with the expression ofmul-
tiple genes, as in the examples of cg18711369 and cg10909506 on
chromosome 17 (ORMDL3 andGSDMB in CD41 T cells; see Fig
E4 in this article’s Online Repository at www.jacionline.org). To
distinguish instances of probable DNAm-mediated genetic
regulation of transcription from alternative regulatory models
(Fig 4, A), we performed CIT (see this article’s Methods section
in the Online Repository).44 As input, we included all triplets
identified in our cis-meQTL and eQTM analyses (RA risk variant,
CpG site, and transcript). In CD41 T cells, CIT highlighted
site-specific DNAm as a probable regulatory intermediate be-
tween risk variant-meQTLs and eQTMs at 5 risk loci (FDR <
0.05), implicating ANKRD55, JAZF1, ORMDL3, FCRL3,
IL6ST, C11orf10, TAX1BP1, and GSDMB as genes with potential
to confer perturbed immune function via this mechanism in RA.Notably, FCRL3was similarly implicated in B cells and although
ORMDL3, IKZF3, and CCR6 showed statistically significant
methylation-mediated associations (P <.05), they were not robust
to FDR correction in this cell type (Table II). Complete CIT
results are available in Tables E17 and E18 in this article’s Online
Repository at www.jacionline.org. We also performed a CIT
analysis treating transcript levels as a mediator to identify
potential instances of reverse causation, but no such effects
were detected.
Intriguingly, not only do disease-associated SNPs frequently
exhibit pleiotropic meQTL effects at these loci, but impacted
CpGs may in turn regulate the expression of multiple putatively
causal genes. In addition to the GSDMB/ORMDL3 example
given above, the rs6859219 SNP on chromosome 5 provides
an interesting example, with associations between the risk
variant and DNAm at 5 proximal CpG sites (Fig 4, B and C).
Furthermore, methylation status at these sites correlates with
FIG 3. A, Relative enrichment of RA risk-associated CpGs at primary TH-cell– and B-cell–specific chromatin
states defined by the Roadmap Epigenomics project40 (15 chromatin states collapsed into indicated 5
groups indicated in key; see this article’s Methods section in the Online Repository). Relative chromatin
enrichments were calculated using the Fisher exact test, *P < .05; **P < .01; ***P < .001; ****P < .0001;
*****P < .00001. B, Top 10 biological gene ontology processes enriched at risk CpG-associated genes in
T cells (top) and B cells (bottom). Relative enrichment of MS (C), asthma (D), and OA (E) risk-associated
CpGs at primary TH-cell– and B-cell–specific chromatin states, analogous to Fig 3, A.
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(Fig 4, C), and CIT confirmed that DNAm at 4 of these sites
(cg21124310, cg10404427, cg23343972, and cg15431103)
likely regulates transcription of both ANKRD55 and IL6ST.
The risk variant and 2 of the CpG sites displaying the strongest
association in CIT analysis (cg21124310 and cg10404427) mapto an intronic enhancer at the ANKRD55 gene. Using publicly
available capture Hi-C data from CD41 T cells,49 we noted
that this intronic enhancer physically interacts with the IL6ST
promoter, potentially explaining this coregulation in 3D space
(see Fig E5 in this article’s Online Repository at www.
jacionline.org).
J ALLERGY CLIN IMMUNOL
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=TABLE II. CIT identifies genes for which DNAm likely mediates RA genetic risk
Gene CpG Lead meQTL SNP Bayes colocalization PP4* Locus CIT P value CIT Permutation FDR
CD41 T cell
ANKRD55 cg21124310 rs6859219 1.00 5q11.2 1.11 3 1024 7.06 3 1024
cg10404427 rs6859219 1.00 .0057 0.0044
cg23343972 rs6859219 1.00 .0062 0.0069
cg15431103 rs6859219 0.95 .0496 0.0319
JAZF1 cg07522171 rs2189966 0.97 7p15.1 3.97 3 1024 0.0035
cg11187739 rs4722758 0.99 .0035 0.0044
cg16130019 rs917117 0.99 .0529 0.0319
ORMDL3 cg18711369 rs12946510 0.86 17q12 4.46 3 1024 0.0035
cg10909506 rs12946510 0.93 .0016 0.0044
FCRL3 cg17134153 rs2210913 0.99 1q23.1 .0027 0.0044
cg01045635 rs2210913 0.99 .0120 0.0296
IL6ST cg15431103 rs6859219 0.95 5q11.2 .0100 0.0296
cg15667493 rs6859219 0.99 .0139 0.0296
cg10404427 rs6859219 1.00 .0216 0.0305
cg21124310 rs6859219 1.00 .0349 0.0305
cg23343972 rs6859219 1.00 .0352 0.0305
C11orf10 cg16213375 rs61897793 1.00 11q12.2 .0163 0.0296
TAX1BP1 cg11187739 rs4722758 0.99 7p15.1 .0470 0.0305
GSDMB cg18711369 rs12946510 0.86 17q12 .0277 0.0305
cg10909506 rs12946510 0.93 .0448 0.0305
B cell
FCRL3 cg19602479 rs2210913 0.99 1q23.1 4.69 3 1024 0.0420
cg01045635 rs7522061 0.97 5.49 3 1024 0.0420
CCR6 cg15222091 rs3093025 0.98 6q27 .0101 0.0966
cg19954286 rs3093025 0.98 .0258 0.1330
cg05094429 rs3093025 0.96 .0347 0.1330
IKZF3 cg18691862 rs9903250 0.44 17q12 .0249 0.1330
ORMDL3 cg12749226 rs11557466 0.97 17q12 .0249 0.1330
For the top results in CD41 T cells and B cells, we report the raw omnibus CIT P value, and FDR value calculated using 1000 permutations.44 Here, we report all instances of
P < .05, highlighting those that satisfy the FDR 0.05 threshold. In instances whereby CIT implicates multiple Illumina probes for the same gene, we report the most statistically
significant probe. Results from all CITs across both cell types are available in Tables E17 and E18.
*PP4 from the Bayesian colocalization analysis38 reports the previous probability that the associations with RA susceptibility and DNAm levels shared the same common genetic
variant; only reported where PP4/PP3 > 5 (see this article’s Methods section in the Online Repository at www.jacionline.org).
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highlights shared etiology at common IMD loci
The above approach was applied to GWAS loci from studies of
MS, asthma, and OA to highlight potential overlap in genetic
etiology. Hence, across 55 independent (r2 > 0.8) MS-associated
cis-meQTLs in CD41 T cells, 36 unique eQTMs were mapped,
comprising 16 unique genes (Table E15), with CIT indicating
a putative DNAm-mediated regulatory model at 11 of these
(Fig 5; Table E17). Although 15 unique genes were similarly
highlighted in B cells (Table E16), no methylation-mediated rela-
tionships were identified (FDR < 0.05; Fig 5; Table E18). Across
the 59 asthma-associated CD41 T-cell cis-meQTLs, 27 eQTMs
comprised 11 unique genes (Table E15), with DNAm a likely reg-
ulatory intermediary at 4 of these (DNAm-mediated gene expres-
sion was not confirmed at any of 30 similarly identified eQTMs inFIG 4. DNAm-mediated transcriptomic regulation of AN
5q11.2 in CD41 T cells. A, Potential regulatory models e
variants and associations with both DNAm status at C
genes. B, The RA risk variant rs6859219 (red line) at c
intronic and 1 intergenic (cg23343972) CpG sites (gray
(yellow). Blue lines indicate the position of all CpG sites
eQTM plots for 3 of the 5 CpG sites associated with
displayed with CIs for each genotype subset; black dott
All 5 CpGs in Fig 4, B, displayed associations with trans
IL6ST genes, and CIT confirmed methylation-mediate
cg10404427, cg23343972, and cg15431103 (Table II).B cells; Fig 5; Table E18). Conversely, at OA risk loci, no
DNAm-mediated relationships were revealed by CIT after
controlling for FDR (Fig 5; Tables E17 and E18).
A considerable degree of overlap in genes likely subject to
DNAm-mediated regulation was observed across the 3 IMDs in
CD41 T (but not B) cells, highlighting cellular mechanisms of
genetic risk that may be shared between disease phenotypes
(Fig 5).Validation of cis-meQTL regulatory effect on causal
gene expression at RA risk loci
We validated cis-meQTL effects at 3 loci implicated by CIT
(cg21124310/ANKRD55, cg07522171/JAZF1, and cg17134153/
FCRL3) in an independent cohort of 39 patients with earlyKRD55 and IL6ST at the risk locus on chromosome
xplaining the association between genotype at-risk
pGs in cis and transcriptional activity at proximal
hromosome 5q11.2 is associated with DNAm at 4
circles), mapping to CD41 T-cell enhancer elements
included in themeQTL analysis. C,meQTL (top) and
the rs6859291 risk variant; linear regression lines
ed line depicts linear regression across all samples.
cript levels of both the ANKRD55 and the upstream
d regulation of these transcripts for cg21124310,
FIG 5. MeQTL-mediated transcriptomic regulation highlights shared etiology at common IMD loci. Venn
diagrams showing the overlap of genes targeted by RA, MS, asthma, and OA risk loci for whom the genetic
effect on expression in CD41 T cells (A) and B cells (B) is mediated by DNAm according to CIT.
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presence of a proxy SNP (rs7522061)within theFCRL3 transcript
that is in high LD (r2 > 0.9 in Europeans, EUR) with the lead reg-
ulatory meQTL SNP (rs2210913; Table II) enabled us to perform
allelic expression imbalance analysis to confirm the eQTL effect
at this locus in CD41 T cells. By quantifying relative allelic pro-
portions at the proxy SNPwithin the genomic DNA andmRNA of
a cohort of patients heterozygous at the regulatory SNP, we found
the frequency of the risk variant (T at rs2210913, C at rs7522061)
to be greatly enriched in mRNA (Fig 6, D). The lead meQTL
variant (rs2210913) is in perfect LD (r2 > 0.99) with an SNP
(rs7528684) that has been functionally validated as an eQTL
variant associated with autoimmunity.50 We cloned this FCRL3
promoter region containing rs7528684, as well as cg17134153
and cg01045635 (see Table II), into the pCpGl CpG-free vector
harboring a luciferase reporter gene.51 Following transfection
into Jurkat cells, transcriptional activity at the risk allele (C at
rs7528684) was approximately 28-fold increased relative to the
empty vector, and approximately 2.3-fold increased relative to
the alternate (T) allele (Fig 6, E), confirming observations from
allelic expression analysis. Crucially, in vitro methylation of the
promoter region before transfection ablated this transcriptional
activity regardless of the allele present, confirming that
DNAm-associated transcriptional repression occurs downstream
of the allelic effect (Fig 6, E), and providing clear experimental
corroboration of previous statistical inference. The absence of
an appropriate transcript SNP precludes allelic expression
analysis at the other loci of interest; nonetheless, expression
data for these samples were able to validate eQTL effects
(Fig 6, F and G). Patients’ demographic data for the (me/e)QTL
validation cohorts are detailed in Table E19 in this article’s Online
Repository at www.jacionline.org.Multiple meQTLs acting in trans show evidence of
phenotype-specific effects
At the experiment-wide FDR threshold, 13,908 trans
SNP-CpG associations (>_1 Mb) were identified in CD41 T cells
and 17,697 in B cells, of which 294 and 479 were independent
after accounting for patterns of LD (Fig 1, A; see Tables E20
and E21 in this article’s Online Repository at www.jacionline.
org), representing 239 and 387 individual CpGs, respectively.
A total of 139 CpGs were regulated in trans in both cell types,
again indicating a considerable degree of shared effects (see Fig
E6, A, in this article’s Online Repository at www.jacionline.
org). Most of the trans effects were interchromosomal (69.4%
in CD41 T cells, 71.6% in B cells). In contrast to the limited
number of disease-specific effects highlighted in cis, interaction
analysis identified a number of transmeQTL effects that differed
significantly by disease phenotype: 3 independent examples were
demonstrated in CD41 T cells (Fig E6, B; Table E5) and 21 in B
cells (Fig E6, C; Table E5). However, no such effects localized to
RA risk loci.DISCUSSION
We present an integrated analysis of DNAm and paired
transcriptomic data in genotyped CD41 T and B cells of
treatment-naive patients with early RA and disease controls.
The study’s comprehensive molecular approach, directed at
functionally relevant cellular compartments during disease
induction, recognizes the relevance of biological context in an
effort to unravel mechanisms of genetic risk. Indeed, the
imperative to study genetic regulation at the level of
defined cell populations is reinforced by our study, in which
more than 30% cis-regulated CpGs were subset specific to either
FIG 6. Validation of CD41 T-cell meQTL and eQTL effects in independent patient cohorts. DNAm was
quantified at (A) cg17134153 (FCRL3 locus), (B) cg07522171 (JAZF1 locus), and (C) cg21124310 (ANKRD55
locus) in CD41 T cells using pyrosequencing. D, FCRL3 allelic expression imbalance analysis of individuals
heterozygous for the transcript SNP rs7522061. E, In vitro luciferase reporter analysis of the FCRL3 promoter
region containing the rs7528684 SNP and CpG sites cg17134153 and cg01045635 (see text and this article’s
Methods section in the Online Repository). Mean 6 95% CI of 3 independent experiments are presented;
****P < .0001, Mann-Whitney U test. F and G, Validation of CD41 T-cell eQTL effects for ANKRD55 and
JAZF1, respectively.
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12 CLARK ET ALCD41 T cells or B cells. As a whole, our findings provide an
essential resource for the functional interpretation of GWAS
and epigenome-wide association studies in RA, having further
implications for IMD more generally.
Most significantly, we confirm the capacity of DNAm to act as
an intermediary between disease-associated genetic variation and
gene expression at a cellular level. Thirty-seven percent (41 of
112) of RA risk loci were found to harbor meQTL variants in
CD41 T and/or B cells in our study, and many of the affected
CpGs in turn likely influenced transcriptional activity. In most
cases, inverse association between DNAm and gene expression
was consistent with a repressive function of methylation at gene
promoters.16 The intronic RA SNP, rs6859219, at the
chromosome 5q11.2 risk locus is striking for its robust association
with autoantibody seronegative as well as seropositive RA.52
Here, the variant potentially regulates expression of 2 causal can-
didates in CD41 T cells—IL6ST, which encodes the common
cytokine receptor gp130, and ANKRD55 whose function remains
unknown—and appears to do so via both intergenic (cg23343972)
and intronic (cg21124310, cg10404427) CpGs.
A further example of this phenomenon arises at the 17q12
locus, where the RA-associated variant mediates transcriptional
repression of ORMDL3, likely doing so via increased methyl-
ation of at least 2 CpGs in CD41 T cells. In addition to corrob-
orating a mechanism of genetic risk previously proposed in
asthma,53 the finding is intriguing given the recently character-
ized function of the gene product in suppressing IL-2 produc-
tion by these cells.54 Our observations at this locus also
illustrate the pleiotropic potential of site-specific methylation
to mediate the expression of putatively causal genes. Accord-
ingly, methylation at the cg18711369 position functions as an
eQTM for GSDMB as well as ORMDL3. We also found
convincing evidence for DNAm-mediated eQTL effects at the
JAZF1 gene, whose product is suggested to regulate proinflam-
matory signaling via p38 mitogen-activated protein kinase and/
or nuclear factor kappa B,55 and the FCRL3 gene. In relation to
the latter, our experimental findings strongly support the direc-
tionality of observed associations, providing confidence in the
CIT analytical approach generally—although the possibility
that distinct variants in strong LD exert independent effects
on DNAm and gene expression cannot be definitively
excluded.56
Our study suggests that discrete genetic risk mechanisms span
IMD phenotypes. For example, strong evidence is found for
site-specific DNAm as an intermediary via which disease
variants regulate ORMDL3, GSDMB, and JAZF1 expression by
CD41 T cells in RA, MS, and asthma, and a similar mechanism
in relation to ANKRD55 and IL6ST is limited to RA and MS. In
contrast, equivalent regulation of FCRL3 expression appeared
unique to RA in our study, albeit in both CD41 and B cells.
A concerted effort to understand the role of these putatively causal
genes in lymphocyte pathobiology during the earliest stages of
IMD (including RA) could pay dividends in the clinic, and should
now be prioritized.
A tendency for the strongest meQTL regulatory effects to
occur preferentially in cis in both cell types is congruent with
previous findings from a range of tissues.9,13,15 Although
increasing population sizes will be required to comprehensively
map trans-meQTLs genome-wide, we do observe interchromo-
somal effects, many of which appear to be active in both celltypes. Moreover, meQTL associations whose effects differ
significantly between patients with RA and disease controls
occurred predominantly in trans. Although preliminary, this
may highlight regulatory effects that reflect the natural history
of the inflammatory/immune pathology during early disease.
Notably, instances of context-specific transcriptional regulation,
dependent on disease state or exposure of cells to external stim-
uli, have been described.26,27 Examples of cis-regulation of
DNAm that is specific to patient cohorts has been described
in autoimmunity.57
In summary, we have demonstrated the central role of DNAm
as an intermediary in regulating the lymphocyte transcriptome,
highlighting molecular pathways through which genetic variation
might confer dysregulated cellular function in RA and
etiologically related IMDs. In so doing we highlight mechanisms
of genetic risk in complex disease generally, prioritizing causal
genes and tractable pathways for study as mediators of adaptive
immune dysregulation. Emerging approaches for targeting
site-specific DNAm in vivo58 may build on observations such as
ours, raising the prospect of personalized therapeutic approaches
to restore immune tolerance and effect cures for complex disease
in the future.
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Key messages
d DNAm associated with genetic variants at RA risk loci
likely mediates causal gene expression in CD41 and B
lymphocytes.
d This mechanism is common to IMDs with overlapping
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